Cognitive · Peptide Reference · Updated 2026-05-11

Selank

Russian-developed synthetic heptapeptide derived from tuftsin. Anxiolytic without sedation or dependence; used clinically in Russia for generalized anxiety disorder. Limited Western clinical trials.

Cognitive Evidence grade: C Not FDA-approved
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Key facts

Class
Synthetic heptapeptide (tuftsin analog)
Route
Intranasal
Pharmacy pathway
503A compounding
Clinical use (Russia)
Generalized anxiety disorder, asthenia
Mechanism
Modulates GABA, BDNF, enkephalin systems
Common dose
300 mcg intranasal 2-3x daily
Evidence grade
C (Russian clinical use)
FDA status
Not FDA-approved

Mechanism of action

Russian-developed synthetic heptapeptide derived from tuftsin. Anxiolytic without sedation or dependence; used clinically in Russia for generalized anxiety disorder. Limited Western clinical trials.

Standard dosing

Typical clinical use: 300 mcg intranasal 2-3x daily. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. Selank requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved. Compounded peptides are dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Patients should request the pharmacy of record and certificates of analysis (USP <71> sterility, USP <85> endotoxin, HPLC potency) for every shipment.

U.S. telehealth providers prescribing Selank

The most commonly cited U.S. telehealth providers for Selank are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD — all of which offer prescriber-supervised access with lab integration and 503A pharmacy partnerships. See the full provider directory for complete profiles.

Trade-offs to know

Selank carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved (when applicable), cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that publishes pharmacy of record, per-vial CoAs, and lab-integrated follow-up.

Related peptides in the cognitive category

Editorial team

Authored by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →

References

  1. Medvedev VE, Tereshchenko OV, Israelyan AY, Chobanu IK. Optimization of treatment for anxiety and asthenic disorders in patients with cardiovascular diseases: results of administering the anxiolytic drug Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):17-22. PMID: 25001774
  2. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic drug Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454102

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.